The May jobs report adds 139K jobs, but mixed signals from BLS, JOLTS, and ADP data suggest labor market weaknesses.

The fund just hit a 52-week high and moved up 176.1% from its 52-week low price of $8.50/share. Are more gains in store for this ETF? Let us take a quick look at the fund and the near-term outlook ...

The fund just hit a 52-week high and is up 17.35% from its 52-week low price of $58.55/share. But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term ...

The trend is your friend is a well-known Wall Street catchphrase that often has proven to be correct. Depending on the nature of the trend, it is frequently used to buy and sell stocks, adjust ...

A greater proportion of patients receiving nerandomilast had diarrhea. SAN FRANCISCO — Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, reduced FVC decline vs. placebo in ...

Oil and gas giant Chevron has an industry-leading breakeven point on its upstream portfolio. The company can support its massive capital return program without jeopardizing its financial health ...

UroGen Pharma shares fell to a 52-week low after a Food and Drug Administration document indicated disagreements with the company about certain aspects of studies of bladder cancer drug UGN-102.

Novo has plunged over 55% since its 52-week high. Charter Communications surged following news of a planned merger with its cable rival, Cox Communications. The deal would create the nation’s ...

Shares of Omeros fell after the company reported lower royalties after sales of its partner Rayner fell. The stock fell 14% to $3.42 after touching a 52-week low. Shares have risen 3.2% over the ...